Allergan Inc (AGN) 169.91 $AGN
The Best S&P 500 Stocks of the Month
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 03, 10:35AM CDT
The S&P 500 had a reasonably good month in April, with the index rising 0.6% and achieving its best monthly close ever. But several stocks blew the lights out, with impressive gains that far exceeded what the broader market gave investors....
A White Knight Riding to the Rescue?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 9:36AM CDT
Valeant Pharmaceuticals has teamed up with Pershing Capital, which owns nearly 10% of Allergan , in an effort to acquire the remaining 90% of the company. However, as Allergan looks to have an excellent growth runway ahead, there may be a number...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 3:45PM CDT
Pfizer (PFE) has an Earnings ESP of -1.82% with a Zacks Rank #4 (Sell).
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
After Yesterday's Rally of 1.72% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 01, 3:44PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $165.96 to a high of $170.05. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $169.29 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Glaxo Misses on Q1 Earnings, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 1:14PM CDT
Glaxo (GSK) reported first quarter core earnings of 70 cents per American depositary shares.
Stocks Turn Mixed: Valeant Retakes 50-Day Line
at Investor's Business Daily - Thu May 01, 12:35PM CDT
Stocks lost steam and turned mixed Thursday afternoon, as indexes wavered amid a barrage of earnings reports and mixed economic data. The Nasdaq was up 0.6% after rising 0.8% earlier. The S&P 500 edged up 0.1%. But the Dow Jones industrial average...
Merger & Acquisition Updates, Quarterly Earnings Releases, and Clinical Trial Results - Analyst Notes on Allergan, Amgen, Furiex, Teva and Alexion
PR Newswire - Thu May 01, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Furiex Pharmaceuticals Inc. (NASDAQ: FURX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1902-100free.
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
United States Migraine Drug Forecast and Market Analysis to 2023: Epidemiology, Etiology, Symptoms, Diagnosis, Pathology and Treatment Guidelines
M2 - Wed Apr 30, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hh5c/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023" report to their offering. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan. Scope - Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms - Premonitory Phase - Aura Phase - Headache Phase - Postdrome Phase 4 Disease Management - Treatment Overview - Acute Migraine Treatment - Preventive Migraine Treatment 5 Competitive Assessment - Product Profiles- Major Brands - Triptans - Imitrex (sumatriptan) - Zomig (zolmitriptan) - Amerge (naratriptan) - Maxalt (rizatriptan) - Axert (almotriptan) - Frova (frovatriptan) - Relpax (eletriptan) - Sumavel DosePro (sumatriptan) - Ergot Alkaloids - Beta Blockers - Anti-Epileptics - Antidepressants - Calcium Channel Antagonists - Botox (onabotulinum toxin A) 6 Opportunity and Unmet Need 6.1 Overview - A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders - Lack of Acute Therapies for Patients Unresponsive to Triptan Medication - Lack of Diagnostic Tools Causes Misdiagnosis - Physician Education - Effective and Well-Tolerated Prophylactic Therapies 6.2 Unmet Needs Gap Analysis - Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication - Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies - Physician Education - Diagnostic Tools 7 Pipeline Assessment - Zecuity - Levadex - RHB-103 - AVP-825 - Lasmiditan - MK-1602 - SUD-001 - RT-001 - NXN-188 8 Market Outlook - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/h6...harmapoint
Allergan Shares Up 31.1% Since SmarTrend's Buy Recommendation (AGN)
Comtex SmarTrend(R) - Wed Apr 30, 9:11AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 weeks, Allergan has returned 31.13% as of today's recent price of $165.18.
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Finish Higher on Solid Earnings
at The Street - Tue Apr 29, 3:14PM CDT
Stocks close higher Tuesday amid a solid spate of earnings, even as economic reports suggest a muted beginning to the year. Easing geopolitical tensions in Ukraine help boost sentiment.
Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry
Business Wire - Tue Apr 29, 2:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/l62h48/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering.
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
The Best S&P 500 Stocks of the Month
Dan Caplinger, The Motley Fool - Motley Fool - Sat May 03, 10:35AM CDT
The S&P 500 had a reasonably good month in April, with the index rising 0.6% and achieving its best monthly close ever. But several stocks blew the lights out, with impressive gains that far exceeded what the broader market gave investors....
A White Knight Riding to the Rescue?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 9:36AM CDT
Valeant Pharmaceuticals has teamed up with Pershing Capital, which owns nearly 10% of Allergan , in an effort to acquire the remaining 90% of the company. However, as Allergan looks to have an excellent growth runway ahead, there may be a number...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 3:45PM CDT
Pfizer (PFE) has an Earnings ESP of -1.82% with a Zacks Rank #4 (Sell).
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
After Yesterday's Rally of 1.72% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 01, 3:44PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $165.96 to a high of $170.05. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $169.29 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Glaxo Misses on Q1 Earnings, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 1:14PM CDT
Glaxo (GSK) reported first quarter core earnings of 70 cents per American depositary shares.
Stocks Turn Mixed: Valeant Retakes 50-Day Line
at Investor's Business Daily - Thu May 01, 12:35PM CDT
Stocks lost steam and turned mixed Thursday afternoon, as indexes wavered amid a barrage of earnings reports and mixed economic data. The Nasdaq was up 0.6% after rising 0.8% earlier. The S&P 500 edged up 0.1%. But the Dow Jones industrial average...
Merger & Acquisition Updates, Quarterly Earnings Releases, and Clinical Trial Results - Analyst Notes on Allergan, Amgen, Furiex, Teva and Alexion
PR Newswire - Thu May 01, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Furiex Pharmaceuticals Inc. (NASDAQ: FURX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1902-100free.
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
United States Migraine Drug Forecast and Market Analysis to 2023: Epidemiology, Etiology, Symptoms, Diagnosis, Pathology and Treatment Guidelines
M2 - Wed Apr 30, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hh5c/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023" report to their offering. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan. Scope - Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms - Premonitory Phase - Aura Phase - Headache Phase - Postdrome Phase 4 Disease Management - Treatment Overview - Acute Migraine Treatment - Preventive Migraine Treatment 5 Competitive Assessment - Product Profiles- Major Brands - Triptans - Imitrex (sumatriptan) - Zomig (zolmitriptan) - Amerge (naratriptan) - Maxalt (rizatriptan) - Axert (almotriptan) - Frova (frovatriptan) - Relpax (eletriptan) - Sumavel DosePro (sumatriptan) - Ergot Alkaloids - Beta Blockers - Anti-Epileptics - Antidepressants - Calcium Channel Antagonists - Botox (onabotulinum toxin A) 6 Opportunity and Unmet Need 6.1 Overview - A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders - Lack of Acute Therapies for Patients Unresponsive to Triptan Medication - Lack of Diagnostic Tools Causes Misdiagnosis - Physician Education - Effective and Well-Tolerated Prophylactic Therapies 6.2 Unmet Needs Gap Analysis - Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication - Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies - Physician Education - Diagnostic Tools 7 Pipeline Assessment - Zecuity - Levadex - RHB-103 - AVP-825 - Lasmiditan - MK-1602 - SUD-001 - RT-001 - NXN-188 8 Market Outlook - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/h6...harmapoint
Allergan Shares Up 31.1% Since SmarTrend's Buy Recommendation (AGN)
Comtex SmarTrend(R) - Wed Apr 30, 9:11AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 weeks, Allergan has returned 31.13% as of today's recent price of $165.18.
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Finish Higher on Solid Earnings
at The Street - Tue Apr 29, 3:14PM CDT
Stocks close higher Tuesday amid a solid spate of earnings, even as economic reports suggest a muted beginning to the year. Easing geopolitical tensions in Ukraine help boost sentiment.
Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry
Business Wire - Tue Apr 29, 2:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/l62h48/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering.
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
